Pharmeasy, a once IPO-bound healthtech valued at over $5 billion, is engaging in dubious business practices, putting its 3.9 million customers’ health at risk, an investigation by The Ken has found. Former executives and pharmacists say that Pharmeasy pushes private-label supplements and generic medicines to boost margins amid pressure to show profitability. Teleconsultations are inadequate, with doctors prescribing supplements without proper patient history, as the company prioritizes hitting sales targets over ethical practices.
